Off-Label Use of Bumetanide for Brain Disorders: An Overview
Bumetanide (BTN or BUM) is a FDA-approved potent loop diuretic (LD) that acts by antagonizing sodium-potassium-chloride (Na-K-Cl) cotransporters, NKCC1 (SLc12a2) and NKCC2. While NKCC1 is expressed both in the CNS and in systemic organs, NKCC2 is kidney-specific. The off-label use of BTN to modulate...
Main Authors: | Shivani C. Kharod, Seok Kyu Kang, Shilpa D. Kadam |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2019.00310/full |
Similar Items
-
Effect of Co-administration of Bumetanide and Phenobarbital on Seizure Attacks in Temporal Lobe Epilepsy
by: Reza Rahmanzadeh, et al.
Published: (2018-11-01) -
Long-term administration of bumetanide improve functional recovery after spinal cord injury in rats
by: Shiva Hashemizadeh, et al.
Published: (2022-10-01) -
Failure of the Nemo trial: bumetanide is a promising agent to treat many brain disorders but not newborn seizures
by: Yehezkel eBen-Ari, et al.
Published: (2016-04-01) -
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
by: Dorinde M. van Andel, et al.
Published: (2020-05-01) -
Role of NKCC1 and KCC2 in Epilepsy: From Expression to Function
by: Ru Liu, et al.
Published: (2020-01-01)